03/20/23 7:18 AMOTC : APLIF Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone HoldingsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement with Long Zone Holdings Inc., amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022.RHEA-AIneutral
02/14/23 7:18 AMOTC : APLIF earningsAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022. “Over the past couple of months, it has been an immense honor to serve as the company’ s CEO and I’ m...RHEA-AIneutral
01/17/23 7:12 AMOTC : APLIF managementAppili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine ProgramAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of...RHEA-AIneutral
01/13/23 7:19 AMOTC : APLIF Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of MetronidazoleAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’ s liquid oral reformulation of the antibiotic metronidazole.RHEA-AIneutral
11/14/22 7:45 AMOTC : APLIF partnershipAppili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force AcademyAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency in partnership with the U.S. Air Force Academy, will provide at least US $14 million in funding over...RHEA-AIneutral
11/10/22 7:38 AMOTC : APLIF earningsAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022. “We continue to move significantly closer to being able to provide a safe and effective vaccine...RHEA-AIneutral
09/22/22 6:43 PMOTC : APLIF Appili Therapeutics Announces Results of Annual and Special Meeting of ShareholdersAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today. Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the...RHEA-AIneutral
08/12/22 4:54 PMOTC : APLIF earningsAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022. “As threats from both known and emerging infectious diseases loom around the world, I’ m proud that Appili...RHEA-AIneutral
08/02/22 7:38 AMOTC : APLIF conferencesAppili Therapeutics to Present at WorldLeish7 Conference in Cartagena, ColumbiaAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili...RHEA-AIneutral
06/29/22 7:49 AMOTC : APLIF earningsAppili Therapeutics Reports Fiscal Year 2022 Financial and Operational ResultsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’ s strategy for fiscal 2023. “Over the past several months, we have enhanced our global partnerships and...RHEA-AIneutral